Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

in Huntington's

disease patients;

-- Completed the Phase 1 portion of the trial, in which Dimebon was safe

and well tolerated, and the Phase 2 portion remains ongoing;

Hormone-Refractory Prostate Cancer

-- Began an open-label Phase 1-2 clinical trial in hormone-refractory

prostate cancer patients;

-- Reported early, positive data showing encouraging, dose-dependent

reductions in serum prostate-specific antigen (PSA) in our two lowest

dosing groups;

-- Based on these results, received approval to expand the size of the

trial and now expect to enroll approximately 100 patients, including

both chemotherapy naive patients as well as patients who have failed

prior chemotherapy;

Strengthened Management Team and Financial Position

-- Appointed Rohan Palekar, a 16-year marketing executive from Johnson &

Johnson's Centocor division as chief commercial officer to lead

commercialization activities for all of our product candidates;

-- Promoted Michele Bronson, Ph.D., to vice president of regulatory

affairs, to represent Medivation programs to U.S. and international

regulatory agencies, develop regulatory strategies and oversee quality

and project management; and,

-- Entered into a $100 million committed equity line of credit facility

with Azimuth Opportunity, Ltd., which provides access to committed

capital at times and in amounts of Medivation's choosing.

2007 Financial Results and 2008 Financial Outlook

Medivation reported a net loss of $31.7 million for the year ended December 31, 2007, compared to a net loss of $15.4 million in the prior year. The basic and diluted loss per share for 2007 was $(1.14) on 27.9 million weighted average common shares outstanding compared to a basic and diluted loss per share of $(0.63) on 24.2 million weighted average common shares outstand
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Hi-Bred Biotechnology Leadership ... at Beijing Ag Summit, ... public and private sectors will help increase,farm productivity in the country ... vice president -- DuPont Crop,Genetics Research and Development, told attendees at ...
... 25 IDEXX,Laboratories, Inc. (Nasdaq: IDXX ), today ... 18% to $249.1 million from $211.2 million,for the first ... the,quarter ended March 31, 2008 were $0.43, compared to ... adjusted diluted EPS for the first,quarter grew 21% to ...
... (Nasdaq: KOSN ) will announce its first quarter ... close., The announcement of Kosan,s first quarter 2008 ... live webcast on May 1, 2008 at 1:30,p.m. Pacific ... live,call by dialing 888.680.0878 (US) or 617.213.4855 (international), access,code ...
Cached Biology Technology:DuPont Partnering with China to Increase Farm Productivity 2DuPont Partnering with China to Increase Farm Productivity 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... the Keck School of Medicine of the University of ... estrogen, the female sex hormone, activates genes in breast-cancer ... to eventually lead to new treatments for the disease. ... of the Keck School,s Department of Biochemistry and Molecular ...
... for rare and neglected diseases that include potential treatments ... virus that affects the central nervous system of newborns, ... and a rare lung disease. The six new projects ... for Rare and Neglected Diseases (TRND) program. "These ...
... Nov. 15, 2011 The Los Angeles World Airports (LAWA), ... has awarded a contract modification to Unisys (NYSE: ... system, used to identify the 45,000 airport employees, contractors, police ... The work is an early step in LAWA,s plan ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 2Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 3
... boxes are ideal for use in refrigerators, freezers, or ... Four vibrant colors allow for color coding to project, ... nitrogen drainage or promote cool air circulation. Supplied with ... 81 tubes. Box dimensions: 13 x 13 ...
RABBIT ANTI BACTERIAL HISTIDASE...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
See product name for description....
Biology Products: